Cbt Ar Arfid denied as experimental or investigational by Humana?

Humana's specific coverage criteria for cbt ar arfid are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies CBT-AR for ARFID as Experimental — and Why You Can Appeal

CBT-AR (Cognitive Behavioral Therapy for Avoidant/Restrictive Food Intake Disorder) is a structured psychotherapy protocol with a growing body of published clinical evidence and guideline recognition for ARFID treatment. An experimental or investigational denial from Humana typically means the plan's coverage policy has not yet updated to reflect current clinical consensus, or the specific billing or procedure code used did not map cleanly to the covered service. This type of denial is frequently overturned when the treating clinician provides a well-documented medical-necessity argument citing recognized professional guidelines.

## Why This Is Appealable

Humana's experimental determination must be based on its own published coverage criteria and, for behavioral health services, must also survive Mental Health Parity Act scrutiny. If Humana would cover a comparable evidence-based psychotherapy for a physical health condition without an experimental label, applying a stricter standard to CBT-AR may constitute a parity violation. Experimental denials can also be challenged by demonstrating that the treatment is endorsed by a recognized professional organization or guideline body relevant to eating disorders.

## Federal Appeal Framework

• Internal appeal: File within the deadline on your denial letter. Under ERISA §503 or applicable state law, Humana must provide a full-and-fair review that includes a clinician with relevant expertise.
• External review: Under ACA §2719, experimental and investigational denials are subject to external review by an independent IRO with the relevant clinical expertise. The general window is approximately four months from the original denial — confirm the exact date on your denial letter.
• Mental Health Parity argument: Document the comparable physical-health treatment Humana covers without an experimental label and raise the parity argument at both the internal and external levels.
• Expedited review: Available when standard timelines would seriously jeopardize health; request in writing with the internal appeal.

## Documentation to Gather

1. ARFID diagnosis records — formal DSM-5 diagnosis, clinical severity assessment, and functional impairment documentation. 2. Professional guideline references — a letter from the prescribing clinician citing the relevant guideline organization(s) (e.g., the applicable eating-disorder professional society) that endorse CBT-AR for ARFID. 3. Peer-reviewed literature summary — prepared by the treating clinician; focus on the existence of published evidence, not specific statistics. 4. Prescriber medical-necessity letter — must directly address Humana's experimental criteria, explain the treatment's evidentiary basis, and raise the parity argument if applicable. 5. Functional impairment documentation — nutritional status, growth data (for pediatric patients), and impact on daily functioning from the clinical record.

## Criteria-Mapping Structure

Obtain Humana's current behavioral health coverage policy for CBT-AR or for eating disorder psychotherapy. Copy each criterion Humana used to classify the treatment as experimental. In the adjacent column, cite the guideline endorsement, published evidence, and clinical record facts that rebut each criterion.

## Next Step

If Humana's experimental denial does not cite a specific policy provision, request that information in writing. An experimental denial without a cited policy standard is procedurally weak and strengthens your appeal.